Our understanding of molecular mechanisms of monogenic kidney diseases has significantly deepened in the past decade. As a result, there is growing interest in targeting precisely upstream pathways in disease pathogenesis The role of gene, RNA and small molecule therapeutics is increasingly recognized. This session will illustrate new advances in molecular therapeutics for monogenic kidney diseases.
| Time | Session |
|---|---|
|
11:00
11:20
|
Gene editing in the kidney
Danny Gale
Speaker
|
|
11:20
11:40
|
Small molecules to treat genetic kidney diseases
|
|
11:40
12:00
|
Q&A
|